Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23388159 | 1.00 | CTSD (0.33) | CTSD | |
| SCHEMBL2851519 | 0.97 | CTSD (0.35) | CTSD | |
| Bromide SCHEMBL809754 | 0.94 | CTSD (0.33) | CTSD | |
| Fluoride SCHEMBL14954087 | 0.94 | CTSD (0.33) | CTSD | |
| SCHEMBL14954190 | 0.94 | CTSD (0.33) | CTSD | |
| Iodide SCHEMBL810380 | 0.94 | CTSD (0.33) | CTSD | |
| Formaldehyde SCHEMBL16161196 | 0.89 | CTSD (0.41) | CTSD | |
| Carbon Monoxide SCHEMBL204677 | 0.89 | CTSD (0.36) | CTSD | |
| Formaldehyde SCHEMBL15319409 | 0.89 | CTSD (0.41) | CTSD | |
| SCHEMBL10610781 | 0.87 | CTSD (0.34) | CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115947756-A | Method for synthesizing polyfluoroalkyl aryl ether by directly coupling aryl halide and polyfluoroalkyl alcohol | 西湖大学 | 2023-04-11 | — | — | CN | claimed |
| CN-115850153-A | Preparation method of adjustable isoindole compound | 广东工业大学 | 2023-03-28 | — | — | CN | claimed |
| CN-115710249-A | Preparation method of polysubstituted isoquinoline and 1, 6-naphthyridine compound and common molecular framework of photoelectric material | 广东工业大学 | 2023-02-24 | — | — | CN | claimed |
| CN-115353510-A | Preparation method and application of isoindole compound | 广东工业大学 | 2022-11-18 | — | — | CN | claimed |
| CN-115160211-A | Green synthesis method of isoindolinone compounds | 温州大学 | 2022-10-11 | — | — | CN | claimed |
| CN-115108960-A | Preparation method and application of polysubstituted indole compound | 广东工业大学 | 2022-09-27 | — | — | CN | claimed |
| CN-115057808-A | Synthetic method of Z-3-vinyl substituted isoindolinone compound | 温州大学 | 2022-09-16 | — | — | CN | claimed |
| CN-112939780-B | Synthetic method of indanone derivatives | 浙江大学 | 2022-04-05 | — | — | CN | claimed |
| CN-112939753-B | Synthesis method of 1-indanone compound | 浙江大学 | 2022-04-05 | — | — | CN | claimed |
| CN-110218172-B | Method for preparing N-aryl sulfonamide from indoline and aryl sulfonamide | 常州大学 | 2022-03-22 | — | — | CN | claimed |
| CN-112939780-A | Synthetic method of indanone derivatives | 浙江大学 | 2021-06-11 | — | — | CN | claimed |
| CN-112939753-A | Synthesis method of 1-indanone compound | 浙江大学 | 2021-06-11 | — | — | CN | claimed |
| CN-107892694-B | Preparation method of pyrazolidinone compound containing bridged ring structure | 河南师范大学 | 2020-03-20 | — | — | CN | claimed |
| US-12622909-B2 | Allosteric EGFR inhibitors and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4192454-B1 | AZABICYCLO-AMINO-TRIAZINE COMPOUNDS FOR MODULATING SPLICING FOR THE TREATMENT OF NEUROLOGICAL DISEASES | SKYHAWK THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4716531-A2 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | Board of Regents, The University of Texas System (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-1741693-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ALCOHOLS | NAGOYA IND SCIENCE RES INST (JP) | 2011-08-03 | — | — | EP | disclosed |
| EP-1741693-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ALCOHOLS | Nagoya Industrial Science Research Institute (JP) | 2007-01-10 | — | — | EP | disclosed |
| US-6303805-B1 | COMPLEX FOR OLEFIN OR STYRENE POLYMERIZATION PREPARED BY REACTING TRANSITION METAL COMPLEX AND COMPOUND HAVING AT LEAST TWO FUNCTIONAL GROUPS, HAVING STRUCTURE IN WHICH ANCILLARY LIGANDS OF COMPLEX ARE BRIDGED WITH SAID FUNCTIONAL GROUP | SAMSUNG GENERAL CHEMICAL CO., LTD. (KR) | 2001-10-16 | — | — | US | disclosed |
| EP-1006120-A2 | Metallocene complexes and method of preparing the same | Samsung General Chemicals Co., Ltd. (KR) | 2000-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622909-B2 | Allosteric EGFR inhibitors and methods of use thereof | EGFR, ERBB3, ERBB2 | CTSD 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.